Sol-Gel Technologies Ltd. (SLGL): Price and Financial Metrics

Sol-Gel Technologies Ltd. (SLGL): $1.25

0.13 (-9.42%)

POWR Rating

Component Grades








Add SLGL to Watchlist
Sign Up

SLGL Price/Volume Stats

Current price $1.25 52-week high $5.71
Prev. close $1.38 52-week low $1.16
Day low $1.25 Volume 11,400
Day high $1.39 Avg. volume 13,068
50-day MA $1.52 Dividend yield N/A
200-day MA $2.98 Market Cap 28.91M

SLGL Stock Price Chart Interactive Chart >

Sol-Gel Technologies Ltd. (SLGL) Company Bio

Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea; and TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris. It is also involved in the development of generic dermatological candidates; and formulation and pre-clinical development of early stage product candidates for acne and rosacea, and other dermatological indications. The company was founded in 1997 and is based in Ness Ziona, Israel

SLGL Latest News Stream

Event/Time News Detail
Loading, please wait...

SLGL Latest Social Stream

Loading social stream, please wait...

View Full SLGL Social Stream

Latest SLGL News From Around the Web

Below are the latest news stories about SOL-GEL TECHNOLOGIES LTD that investors may wish to consider to help them evaluate SLGL as an investment opportunity.

Is Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Trading At A 24% Discount?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Sol-Gel Technologies fair value estimate is US$1.87 Sol-Gel...

Yahoo | November 20, 2023

Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023Gorlin Syndrome KOL event to be held on December 6, 2023Sol-Gel maintains cash runway into the second half of 2025 NESS ZIONA, Israel, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved

Yahoo | November 9, 2023

Zacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies

Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies are part of the Zacks Industry Outlook article.

Yahoo | October 31, 2023

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, AMPH and SLGL.

Yahoo | October 30, 2023

Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | October 10, 2023

Read More 'SLGL' Stories Here

SLGL Price Returns

1-mo -3.85%
3-mo -54.55%
6-mo -62.91%
1-year -73.57%
3-year -86.11%
5-year -81.26%
YTD -72.59%
2022 -38.38%
2021 -24.41%
2020 -42.92%
2019 184.88%
2018 N/A

Continue Researching SLGL

Want to see what other sources are saying about Sol-Gel Technologies Ltd's financials and stock price? Try the links below:

Sol-Gel Technologies Ltd (SLGL) Stock Price | Nasdaq
Sol-Gel Technologies Ltd (SLGL) Stock Quote, History and News - Yahoo Finance
Sol-Gel Technologies Ltd (SLGL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!